openPR Logo
Press release

Unfractionated Heparin Market Outlook, and Opportunity Analysis, 2018-2026

08-09-2018 03:24 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Unfractionated Heparin Market Outlook, and Opportunity

Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a natural protein in the body, to block clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when taken orally.

Download PDF Brochure @

Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE) in patients with increased postoperative complications. Unfractionated heparin is the preferred treatment for patients at high risk of bleeding complications, owing to its short activity and reversibility and its reversible anticoagulant effect. Additionally, UTH offers various advantages over other types of heparin, owing to its ability to rapidly enter into the blood stream and less reliant to kidney for extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross the placenta, and thus is considered as safe for the fetus.

Unfractionated Heparin Market Drivers

Growth of unfractionated heparin market is increasing, owing to the increasing incidence of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and among others. According to the data findings published in the Centers for Disease Control and Prevention (CDC), in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year in the U.S. due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE). According to data published in the Circulation Research Journal: a journal of the American Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with increasing age. According to the same source, in the U.S., study estimated the age-stratified incidence showing 143 per 100000 among ages 40 to 49 years, 200 per 100 000 among ages 50 to 59 years, 391 per 100000 among ages 60 to 69 years, 727 per 100000 among ages 70 to 79 years, and 1134 per 100000 among ages ≥80 years. Additionally, the low awareness regarding the pulmonary embolism and deep-vein thrombosis showing the negligence towards the early diagnosis of these condition. Moreover, healthcare regularity organizations are engaged in increasing the awareness for the same, which will expected to drive the unfractionated heparin market in near future.

However, adverse effects of unfractionated heparin during treatment, poses as a major restraint for growth of the unfractionated heparin market. Heparin?induced thrombocytopenia (HIT), an adverse reaction occurring during treatment with heparin, is associated with inconsistent increase in the clotting causing further complications. For instance, according to the data published in American Society of Hematology in 2017, Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. Furthermore, adults receiving heparin formulation for medical or general surgical indications are at higher risk for HIT than pediatric or obstetric patients.

Moreover, cost-effectiveness of low-molecular weight heparin over the unfractionated heparin in venous thromboembolism (VTE) prevention in critical illness, limits the adoption of unfractionated heparin. According to the data published in the Journal of American Medical Association (AMA), in November 2014, hospital costs per patient using low-molecular weight heparin were a median of US$ 39,508 compared with US$ 40,805 on unfractionated heparin. Moreover, low-molecular weight heparin was found to be more effective and least costly in treating VTE.

Unfractionated Heparin Market - Regional Analysis

On the basis of region, the unfractionated heparin market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading position in the global unfractionated heparin market, owing to increasing prevalence of deep venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000 to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of people die within one month from diagnosis. Additionally, according to the same source, around 5% to 8% of the U.S. population has one of several genetic risk factors, such as inherited thrombophilias, which increases the risk for thrombosis.

Request Sample Copy of this Business Report @

Unfractionated Heparin Market Competitive Landscape

Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO Pharma A/S.

Research advancements in unfractionated heparin are expected to create new applications in the treatment of Chronic Obstructive Pulmonary Disease (COPD). A pilot study performed at the University of Portsmouth in December 2017, evaluated that, the use of inhaled nebulized unfractionated heparin is an effective treatment for moderate-to-severe COPD. Unfractionated heparin significantly improves the lung function and reduces labored breathing.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Unfractionated Heparin Market Outlook, and Opportunity Analysis, 2018-2026 here

News-ID: 1171301 • Views: 206

More Releases from Coherent Market Insights

Global Cryptocurrency Market With Top Companies Bitfinex, BitFury, Bitstamp., Co …
Cryptocurrency are digital medium of exchange, alternative to conventional currencies such as US$ or Euros. These utilize digital information exchange based on the principles of cryptography, to provide secure means of transactions and in many cases provides anonymity. In 2009, Bitcoin became the first decentralized digital currency, which leads to the introduction of over thousand other digital currencies in the market. The main key players in the industry are- Bitfinex, BitFury
Benelux Power Tool Market With Top Companies Stanley Black and Decker, SKF, Hita …
A power tool is that is operated by an additional power source and mechanism that is used for performing mechanical operations. Power tools are segmented as pneumatic, electric, and hydraulic, of which electric tools are most commonly used. Power tools are used for performing variety of applications namely such as drilling, gardening, construction, household tasks, cutting, shaping, grinding, sanding, polishing, heating, beating, and more. Electric power tools are actuated by
Aircraft Refurbishing Market With Top Companies Diehl Stiftung. KG, Gulfstream A …
Aircraft refurbishing is the process required to ensure the continuing soundness and safety of an aircraft. It includes inspection, overhaul, replacement, defect rectification, and embodiment modifications. Retrofit refurbishing gives a new look to the aircraft, which is comprised of constructing, renovating, and repairing cabin interiors, in order to comply with necessary requirements. Furthermore, it replaces lavatory, overhead bins, sidewalls liners, monuments, windows, cabin lighting, and carpet. In passenger seats refurbishing,
Web Real-Time Communication (WebRTC) Solutions Market With Top Companies Avaya, …
Web real-time communication is a free and open-source project that offers browser-based applications, voice communications, video calls, file sharing, and eliminating need for software plug-ins for the browser. WebRTC utilizes simple application program interfaces (APIs), in order to provide real-time communication to mobile applications and browsers. Furthermore, it makes it easy to incorporate into commercial products and pose it as an attractive option for solution providers. WebRTC finds major applications

All 5 Releases

More Releases for Unfractionated

Unfractionated Heparin Global Industry Report - History, Present and Future 2018
GET SAMPLE REPORT @ The global market size of Unfractionated Heparin is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand,
Unfractionated Heparin Market to Record Sturdy Growth by 2025
The largely consolidated vendor landscape of the global Unfractionated Heparin Market features several large international companies and a handful of well-established local players operating in promising regional markets, states Transparency Market Research in a recent report. To gain a larger control on the market, companies are putting more emphasis on strategic collaborations and expansion in lucrative untapped regional markets. Focus on regional markets such as Asia Pacific and Latin America
Unfractionated Heparin Market Projected to be Resilient During 2025
Global Unfractionated Heparin Market: Overview This report on unfractionated heparin market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing unfractionated heparin products as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments
Global Unfractionated Heparin Market Assessment & Development Forecast during 20 …
Unfractionated heparin is known as a naturally occurring anticoagulant which is primarily in dialysis as well as heart lung machines for the prevention of blood clots. In order to study the market for unfractionated heparin, Market Research Hub (MRH) has included a new research report titled “Unfractionated Heparin Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017- 2025”, to its wide database. This assessment studies the present
Unfractionated Heparin Market Overview and Regional Outlook Study by 2025
The vendor landscape of the global Unfractionated Heparin Market features a largely consolidated nature, with several large international vendors and a handful of local players operating in the market, observes Transparency Market Research in a recent report. With the view of maintaining their strongholds on the market, leading companies are focusing acquiring or entering into strategic mergers and collaborations with promising small-scale vendors in lucrative regional markets. Investments in regional
Global Unfractionated Heparin Market Insights: Premium Market Research Report 20 …
Reports Monitor publishes Global Unfractionated Heparin Market Report 2017-2022 to its database This report is split area wise globally and has included many important regions. The sales, revenue, market share and Growth rate of Unfractionated Heparin Marketof these regions from 2017 to 2022 (forecast) are North America Europe China Japan Southeast Asia India Request a Sample Copy of this Report @  The top competitors for Unfractionated Heparin Marketaccording to the sales volume, Price, (K USD /Unit), Revenue (Million USD),